Friday, 29 September 2017

Rituxan may prolong survival of patients with lymphoma

A new clinical trial conducted at Nantes Medical University in France has found that Rituxan (rituximab) can prolong the life of lymphoma patients.  The trial, conducted on 299 patients younger than 66 when first diagnosed with mantle-cell lymphoma determined that "after four years, 83% of rituximab patients were still alive and progression-free, versus 64% of patients who had standard treatment alone."

To read more about this clinical trial, click here.

No comments:

Post a Comment